Overview
- Samsung agreed to invest $110 million and partner on commercialization in South Korea with potential expansion to Japan and Singapore.
- In the 35,878-participant PATHFINDER 2 study, adding Galleri to guideline screenings increased cancer detection more than sevenfold.
- More than half of cancers detected with Galleri were found at early stages, with 99.6% specificity and 92% tissue-of-origin accuracy reported.
- Grail also raised $325 million in a private placement with institutional investors as it ramps commercialization efforts.
- Shares are up roughly 80% over the past month, though televised host Jim Cramer urged caution after the run-up and the stock has pulled back in recent days.